Cortes Jorge E, Gambacorti-Passerini Carlo, Deininger Michael, Abruzzese Elisabetta, DeAnnuntis Liza, Brümmendorf Tim H
Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Int J Hematol Oncol. 2020 May 29;9(2):IJH26. doi: 10.2217/ijh-2020-0004.
Preclinical studies have shown reproductive toxicity with bosutinib, but little is known about its effects during conception or pregnancy in humans.
Pregnancy cases in patients receiving bosutinib were identified from the Pfizer safety database.
Thirty-three pregnancy reports were identified. Sixteen cases of maternal exposure: six live births, four abortions and six with unknown outcomes. Seventeen instances of paternal exposure: nine live births, five abortions and three with unknown outcomes.
Adverse effects of bosutinib exposure at conception or during pregnancy in humans cannot be excluded, particularly if therapy is not interrupted upon recognition of pregnancy. Contraceptive use is recommended for female patients receiving bosutinib, and patients should be made aware of the potential risks associated with bosutinib use during pregnancy.
临床前研究已显示博舒替尼具有生殖毒性，但对其在人类受孕或孕期的影响了解甚少。
从辉瑞安全数据库中识别出接受博舒替尼治疗的患者中的妊娠病例。
共识别出33份妊娠报告。16例母亲暴露：6例活产、4例流产、6例结局未知。17例父亲暴露：9例活产、5例流产、3例结局未知。
不能排除人类在受孕或孕期接触博舒替尼的不良反应，尤其是在确认怀孕后未中断治疗的情况下。建议接受博舒替尼治疗的女性患者使用避孕药具，并且应让患者了解孕期使用博舒替尼的潜在风险。
